Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy

Trial Profile

Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Therapeutic Use
  • Acronyms ARC001
  • Sponsors Allergen Research Corporation
  • Most Recent Events

    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 06 Mar 2017 According to an Aimmune Therapeutics media release, adherence data from this study were presented today at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
    • 06 Mar 2017 Results published in an Aimmune Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top